<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031456</url>
  </required_header>
  <id_info>
    <org_study_id>PRP- Premature Ovarian Failure</org_study_id>
    <nct_id>NCT04031456</nct_id>
  </id_info>
  <brief_title>Ovarian Autologous Platelet-Rich Plasma (PRP) Treatment in Premature Ovarian Failure.</brief_title>
  <acronym>PRP</acronym>
  <official_title>Estimation of Ovarian Rejuvenation in Women Under Premature Ovarian Failure After Autologous Platelet-rich Plasma Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific prospective Randomnised Clinical Trial, attempts to investigate whether
      autologous Platelet Rich Plasma (PRP) injected into the ovaries of Premature Ovarian Failure
      (POF) patients, may lead to reactivation of the ovarian function.

      Autologous PRP is obtained from the patients' own blood, collected from the peripheral veins,
      prior to the treatment. Following centrifugation, PRP presents with an increased platelet
      concentration. Due to its growth factors and cytokines contained within, PRP is shown to
      stimulate tissue proliferation and growth. Examples of such factors are the vascular
      endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth
      factor (PDGF), transforming growth factor (TGF) and others. PRP has been employed in several
      medical conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. It's
      efficacy in ovarian function has not been fully elucidated.

      The aim of this study is to evaluate the effectiveness of ovarian PRP injection in order to
      reactivate ovarian function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of menstrual cycle regularity</measure>
    <time_frame>6 months</time_frame>
    <description>Regular menstruation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of FSH measured per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of AMH measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of LH measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oestradiol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of E2 measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesteron</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of PRG measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primordial and antral follicular count (AFC)</measure>
    <time_frame>3 months</time_frame>
    <description>Folliculogenesis reactivation TVUS monitoring of the primordial and antral follicular count (AFC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause, Premature</condition>
  <condition>Menopause Related Conditions</condition>
  <condition>Menopausal Syndrome</condition>
  <condition>Premature Ovarian Failure</condition>
  <condition>Ovarian Failure, Premature</condition>
  <arm_group>
    <arm_group_label>Group PRP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women diagnosed with Premature Ovarian Failure receiving ovarian PRP (Platelet Rich Plasma).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women diagnosed with Premature Ovarian Failure receiving placebo - PFP (Platelet Free Plasma).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Platelet Rich Plasma</intervention_name>
    <description>Autologous PRP will be injected into the ovaries.</description>
    <arm_group_label>Group PRP patients</arm_group_label>
    <other_name>PRP</other_name>
    <other_name>Platelet Rich Plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injected into the ovaries.</description>
    <arm_group_label>Control Group - placebo patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with Premature Ovarian Insufficiency

          -  Menstrual cycle irregularities

          -  FSH &gt; 25 IU/L

          -  Karyotype: 46,XX

          -  Willing to comply with study requirements

        Exclusion Criteria:

          -  AMH &gt; 8 pmol/L

          -  Current diagnosis of cancer,

          -  Premature ovarian failure due to a chromosomal abnormalities (Turner Syndrome, Fragile
             X Syndrome)

          -  Ovarian inaccessibility

          -  Endocrinologic disorders (Thyroid Dysfunction, Diabetes mellitus, Metabolic syndrome),

          -  BMI&gt;30 kg/m2, BMI&lt;18.5kg/m2

          -  Systematic autoimmune disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mara Simopoulou, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Agni Pantou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Pantos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

